New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
In a new white paper, Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval and urge policymakers and stakeholders to address the remaining barriers to a competitive marketplace for biologic drugs.
The MGA white paper details barriers to US biosimilars in their second decade in three categories: barriers to access and utilization, barriers to development, and barriers to market entry and sustainability (see Figure 1). With concerted effort, stakeholders can ensure that the next decade of US biosimilars is characterized by a more competitive marketplace along with the additional cost savings that will follow.
